Skip to content
ClinCalc Pro
Menu
Calculators Drugs Pathways AI Dx Donate Get the App
Somatostatin Analogue

Lanreotide

Brand names: Somatuline Autogel

Lanreotide is a long-acting somatostatin analogue used in acromegaly and in the treatment of symptoms and tumour control of neuroendocrine tumours.

Dosing — being independently re-sourced

ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.

Clinical monograph

How it works

It binds somatostatin receptors, predominantly subtypes 2 and 5, inhibiting secretion of growth hormone and various gut hormones and exerting antiproliferative effects on responsive neuroendocrine tumours.

Prescribing in practice

  • It commonly causes gastrointestinal effects and, by reducing gallbladder motility, predisposes to gallstones, so monitor for biliary complications.
  • Given by deep subcutaneous injection at regular intervals; injection technique and site rotation affect tolerability.
  • It can alter glucose homeostasis and may affect requirements for diabetes therapy, so review glycaemic control.

Monitoring

Monitor growth hormone and IGF-1 (in acromegaly) or relevant tumour markers and symptoms, together with blood glucose and gallbladder status.

Counselling the patient

  • Report persistent diarrhoea, abdominal pain, or fatty stools.
  • Seek advice for symptoms suggesting gallstones such as upper abdominal pain after meals.
  • Attend for regular injections to maintain disease control.

Evidence & guidelines

Somatostatin analogues are established in acromegaly and demonstrated antiproliferative benefit in neuroendocrine tumours in the CLARINET trial.

Reference: Endocrine Society Acromegaly Guidelines 2014; CLARINET Trial (NEJM 2014); Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.

Drugs
Pathways